Phase II trial of lazertinib in epidermal growth factor receptor (EGFR) mutation-positive (M+), metastatic non-small cell lung cancer (NSCLC) patients with asymptomatic or mild symptomatic brain metastases after failure of EGFR tyrosine kinase inhibitor (TKI) (KCSG LU20-15).

Authors

Min Hee Hong

Min Hee Hong

Yonsei Cancer Center, Seoul, South Korea

Min Hee Hong , Yoon Ji Choi , Hee Kyung Ahn , Bhumsuk Keam , Yu Jung Kim , Ju Won Kim , Hye Ryun Kim , Jin-Hyoung Kang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT05326425

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 9054)

DOI

10.1200/JCO.2023.41.16_suppl.9054

Abstract #

9054

Poster Bd #

42

Abstract Disclosures